Bharat Parenterals shares surged 25 % over three trading sessions, reaching a 52‑week high of ₹1,895.10 on the BSE and ₹1,898 on the NSE. The stock hit the 20 % upper circuit on Friday, September 25, after the company announced that its board would meet on Tuesday, September 29 to consider a preferential equity issuance. The demand was driven by speculation that the company may raise capital through a new share issue, although the amount was not disclosed.

In a regulatory filing, Bharat Parenterals stated that the Board of Directors would convene on Tuesday, September 29 2026 to evaluate and, if deemed appropriate, approve a proposal for issuing equity shares or other eligible securities by way of preferential issue. The notice also mentioned that trading in the company’s securities by designated persons and their immediate relatives would remain closed for 48 hours following the conclusion of the meeting.

The company reported that its net profit for the first quarter of the current financial year fell 64 % to ₹3.65 crore from ₹10 crore in the same period last year. Revenue from operations declined 42 % to ₹55 crore at the end of the June quarter, compared with ₹94 crore in the year‑ago period. Bharat Parenterals attributed the decline to a base effect, noting that Q1FY26 was the largest revenue quarter in its history, accounting for 40 % of FY26 revenue of ₹234.0 crore and 61 % above the FY26 quarterly average of ₹58.5 crore.

Earnings before interest, taxes, depreciation and amortisation (EBITDA) fell 61 % to ₹6 crore from ₹15 crore, and the EBITDA margin contracted by 540 basis points to 10.8 %. The company highlighted that the Q1FY26 top line was buoyed by the opening tranche of a ₹210 crore institutional order, with delivery spread over eighteen months starting April 2025; the closing tranche of this order will be delivered in Q1FY27.

At 2:21 pm, Bharat Parenterals shares were locked in the 20 % upper circuit on the NSE, with 10,127 buy orders pending and no sellers visible. The 52‑week high reached ₹1,895.10 on the BSE and ₹1,898 on the NSE. Trading by designated persons and their immediate relatives will remain closed for 48 hours after the meeting. The company also noted that its Q1FY26 top line was supported by the opening tranche of a ₹210 crore institutional order, with the closing tranche scheduled for Q1FY27. The article concludes with a disclaimer that the information is for informational purposes and should not be construed as investment advice, urging readers to consult a financial advisor before making decisions.